In March 2025, China's National Medical Products Administration (NMPA) issued Announcement No. 30 [2025] (the "Announcement"), marking a significant recalibration of China's regulatory framework for medical devices being moved from overseas into local manufacturing. The Announcement furthers Beijing's long-standing policy objective of accelerating localization while expanding the practical options available to multinational corporations (MNCs) and cross-border collaborators seeking to manufacture medical devices in China.

At its core, the Announcement broadens the eligibility criteria for transferring imported Class II and Class III medical device registrations from overseas to domestic production. It loosens the restrictive 2020 requirement that the domestic applicant must be an enterprise directly established by the overseas registrant. Under the new regime, the test is now that any domestic entity that shares the same "actual controller" as the original overseas registrant may apply. This shift to a common-control standard significantly increases structuring flexibility, enabling MNCs to leverage existing PRC affiliates, as opposed to having to establish new, single-purpose entities to achieve "Made in China" status.

Licensing, collaboration, and joint-venture structures will henceforth need to be evaluated through the lens of the "actual controller" test. For companies seeking to benefit from expedited localization, equity-based control structures, rather than arm's-length licensing arrangements, may offer a more efficient regulatory pathway.

For MNCs, the primary impact is the mitigation of disadvantages associated with importing against a backdrop of aggressive volume-based procurement and "buy China" preferences. By permitting the reuse of original overseas registration dossiers, including non-clinical and clinical data, NMPA has de facto reduced the time-to-market for domestic versions of global products potentially measured in years rather than months.

Once a domestic registration is granted, subsequent renewals and changes will be handled independently of the original overseas certificate. This provides MNCs with the autonomy to develop domestic products in line with local clinical need, without being tied to global regulatory cycles. At the same time, the requirement for a notarized Letter of Authorization and the transfer of technical dossiers point to the importance of discipline around IP protection. Agreements must clearly delineate data ownership, permitted scope of use, audit rights, and exit protections, particularly where global clinical or manufacturing know-how is being referenced.

Finally, NMPA's emphasis on "substantive equivalence" between overseas and domestic quality management systems underscores that speed cannot come at the expense of compliance. Successful localization strategies will require rigorous gap analyses of quality management systems and proactive regulatory engagement.

In short, localization in China's medical device market is no longer a regulatory checkbox, but reflects China's policy to open the gate wider to inbound medical device production transfer subject to meeting the test for substantive equivalence in the originating jurisdiction's quality management system.